Effect of Omega-3 Fatty Acids on Low Density Lipoprotein Subfraction, Adiponectin and Apolipoprotein B in Type 2 Diabetic Patients.
10.3803/EnM.2011.26.3.218
- Author:
Haejung JUN
1
;
Junghae KO
;
Hyesook JUNG
;
Changshin YOON
;
Taekyoon KIM
;
Minjeong KWON
;
Soonhee LEE
;
Jihye SUK
;
Mikyung KIM
;
Dukkyu KIM
;
Jeong Hyun PARK
Author Information
1. Molecular Therapy Lab, Paik Memorial Institute for Clinical Research, Busan, Korea. pjhdoc@chol.com
- Publication Type:Randomized Controlled Trial ; Original Article ; Clinical Trial
- Keywords:
Adiponectin;
Apolipoprotein B48;
Apolipoprotein B100;
Omega-3 fatty acids;
Small dense LDL cholesterol;
Type 2 Diabetes mellitus
- MeSH:
Adiponectin;
Apolipoprotein B-48;
Apolipoproteins;
Apolipoproteins B;
Blood Glucose;
Cardiovascular Diseases;
Cholesterol;
Diabetes Mellitus, Type 2;
Enzyme-Linked Immunosorbent Assay;
Fasting;
Fatty Acids, Omega-3;
Humans;
Immunoelectrophoresis;
Lipoproteins;
Plasma;
Ultracentrifugation
- From:Endocrinology and Metabolism
2011;26(3):218-224
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Omega-3 fatty acids derived from fish oil have been reported to exert a beneficial effect on reducing cardiovascular disease. Reports about their mechanism have generated several interesting findings, including a change in small dense low density lipoprotein (sdLDL) cholesterol proportion, adiponectin, and apolipoprotein B (apoB), in addition to changes in the lipid profile. The principal objective of our study was to evaluate the effects of omega-3 fatty acids on plasma sdLDL, adiponectin, apoB100, and B48 in type 2 diabetic patients with hypertriglyceridemia. METHODS: We randomized 28 type 2 diabetic patients in a placebo-controlled, double-blind trial to receive either omega-3 fatty acids or placebo, both administered at a dose of 4 g daily for 12 weeks. LDL subfractions prior to and after treatment were separated via low-speed ultracentrifugation and analyzed via immunoelectrophoresis. Adiponectin, apoB100, and B48 levels were measured using an ELISA kit. RESULTS: sdLDL proportions were reduced in the omega-3 fatty acids group by 11% after 12 weeks of treatment (n = 17, P = 0.001), and were reduced by 4% in the control group (n = 11, P = 0.096). The patients receiving the omega-3 fatty acids evidenced a significant reduction in the levels of triglyceride (P = 0.001), apoB100, and B48 after 12 weeks (P = 0.038 and P = 0.009, respectively) relative to the baseline. Omega-3 fatty acids supplementation increased fasting blood glucose (P = 0.011), but the levels of HbA1c in each group did not change to a statistically significance degree. The adiponectin value was not reduced in the omega-3 fatty acids group (P = 0.133); by way of contrast, the placebo group evidenced a significant reduction in adiponectin value after 12 weeks (P = 0.002). CONCLUSION: Omega-3 fatty acid treatment proved effective in the reduction of atherogenic sdLDL and apoB in type 2 diabetic patients (Clinical trials reg. no. NCT 00758927, clinicaltrials.gov).
